Hypertension Clinical Trial
Official title:
to Evaluate the Effect of Food Intake on the Pharmacokinetic of Single Dose SPH3127 Tablets in Chinese Health Subjects
Verified date | November 2021 |
Source | Shanghai Pharmaceuticals Holding Co., Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a single-center, randomized, open, double-cycle and double-cross and self-reflection phase Ic clinical trial, to evaluate effect and safety of high fat diet on pharmacokinetics of SPH3127 tablets. Two panels, each consisting of ten participants (The number of single-sex subjects is not less than 1/3 of the total number) will be randomized to A or B groups.
Status | Completed |
Enrollment | 20 |
Est. completion date | September 30, 2018 |
Est. primary completion date | September 30, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - The body mass index is 19 ~ 26kg/m2 (including the critical value), which allows the minimum weight of male to be 50kg (including the critical value) and 45kg (the critical value) for women. - Before the study, participants have kown about the significance, potential benefits, inconveniences and potential risks of the study and can follow the research's procedure and already sign the informed consent Exclusion Criteria: - Participant who pregnancy, lactating women, and plan to get pregnant within six months after the clinical trial - Participant who has significant abnormal physical examination, laboratory examination results (such as: liver function examination - aspartate aminotransferase (AST) and alanine aminotransferase (ALT) more than 1.5 times that of the upper limit of normal) - Participant who has a history of cardiovascular, liver, kidney, digestive tract, nervous system, blood system, familial hematologic disease, abnormal thyroid function, or mental abnormality - Participant who has drug allergy history, allergy constitution - Participant who took oral contraceptives within 6 weeks - Participant who used any drug (including Chinese herbal medicine) within 1 week - Participant who donated blood within 2 months - Participant who participated clinical trials of any drug in the past 3 months (as subjects) - Participant who has any positive result of virus serology check : human immunodeficiency virus antigen antibody (HIV Ag/Ab) and hepatitis c virus (HCV) - Immunoglobulin G(IgG)antibody to IgG, hepatitis b surface antigen (HBsAg) and treponema pallidum antibody (TP) - Participant who are smoking, drinking, drinking coffee, strong tea and drug abusers - Participant who the researchers believe that there are volunteers who are not suitable for the study |
Country | Name | City | State |
---|---|---|---|
China | The capital medical university affiliated Beijing anzhen hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Shanghai Pharmaceuticals Holding Co., Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Plasma area under curve(AUC)(0-8) of SPH3127 3127 | to evaluate the area under curve(AUC)(0-8) of SPH3127 by feeding | Before dose, and at 0.17 hours?0.33h?0.5h?0.75h?1h?1.25h?1.5h?2h?4h?6h?8h?12h?24h hours after dose | |
Primary | Plasma Cmax of SPH3127 | to evaluate the Cmax of SPH3127 by feeding | Before dose, and at 0.17 hours?0.33h?0.5h?0.75h?1h?1.25h?1.5h?2h?4h?6h?8h?12h?24h hours after dose | |
Primary | Plasma Tmax of SPH3127 | to evaluate the Tmax of SPH3127 by feeding | Before dose, and at 0.17 hours?0.33h?0.5h?0.75h?1h?1.25h?1.5h?2h?4h?6h?8h?12h?24h hours after dose | |
Primary | Apparent terminal half-life of SPH3127 | to evaluate the Apparent terminal half-life of SPH3127 by feeding | Before dose, and at 0.17 hours?0.33h?0.5h?0.75h?1h?1.25h?1.5h?2h?4h?6h?8h?12h?24h hours after dose | |
Secondary | Number of participants with adverse events (AEs) | Incidence and intensity of Adverse Events according to Common Toxicity Criteria (CTC version 4.03) associated with SPH3127 | Baseline to 10-13 days post last dose | |
Secondary | Change from baseline in laboratory hematology values | to evaluate the change from baseline in laboratory hematology values | Baseline to 10-13 days post last dose | |
Secondary | Change from baseline in laboratory chemistry values | to evaluate the Change from baseline in laboratory chemistry values | Baseline to 10-13 days post last dose | |
Secondary | Change from baseline in ECG | to evaluate the from baseline in ECG | Baseline to 10-13 days post last dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A | |
Completed |
NCT04303468 -
Intervention With a GABA Supplement in Prediabetics
|
N/A |